News
Dated, sourced news on peptide trials, regulatory filings and the claims circulating in the research-peptide market, newest first.
- Does the AMA Vote End BPC-157 Compounding? What Its New Policy Can Do
AMA peptide policy: on November 9, 2026 the AMA urged HHS to rescind its BPC-157 compounding policy. What the vote can and cannot change, and what is next.
By Allison Thorne ·
- Health Canada Named Three Bacteria in Seized Peptides. It Did Not Name the Vials
Health Canada's peptide advisory names three bacteria in seized injectables. What it says about retatrutide and tirzepatide, and what it leaves out.
By Allison Thorne ·
- Do GLP-1s Beat Metformin for Prediabetes? No Trial Yet
An observational analysis of 256,492 adults reported a 31% lower diabetes risk for GLP-1 users than metformin users. No randomized trial has compared them, and no confidence interval was reported.
By Allison Thorne ·
- Is FuturHealth Going Out of Business? It Filed Chapter 11
FuturHealth filed Chapter 11 on November 1, 2026, case 26-11748 in Delaware. Chapter 11 is a reorganization, not a closure, and nothing on the record yet establishes what happens to prescriptions.
By Allison Thorne ·
- Can You Get BPC-157 From a Compounding Pharmacy Now? What HHS Allowed
Six named peptides now have a legal route into a compounding pharmacy, on a prescription, and BPC-157 is one of them.
By Allison Thorne ·
- This Pancreatic Cancer Vaccine Did Everything but Work. Then the Explanation Changed
The KRAS vaccine missed its primary endpoint at a hazard ratio of 0.85. Elicio has now explained that miss two different ways, four months apart.
By Allison Thorne ·
- When Will CagriSema Be Approved? What Novo Has Filed
Novo filed in December 2025 and expects a decision in Q4 2026. No PDUFA date is public. The application rests on REDEFINE 1 and 2, not the trial it lost.
- Oral VK2735 Just Entered Phase 3. The Injectable Is a Year Ahead
SUNRISE-1 and SUNRISE-2 test 27.5 mg, 35 mg and 55 mg once daily. The 12.2% figure everyone quotes came from 120 mg, a dose the Phase 3 program does not use.
By Allison Thorne ·
- Has Anyone Died From Retatrutide? What the Two FDA Reports Actually Say
Two unverified FDA reports describe deaths after people used products sold as retatrutide. Nobody has established what was in the vials, and the controlled trials show no cardiac excess.
By Allison Thorne ·
- RYZ101 Just Passed Phase 3. How Does a Peptide Deliver Cancer Treatment?
Bristol Myers Squibb says RYZ101 met its Phase 3 endpoint and released no numbers. What the peptide does, and why actinium is not lutetium.
By Allison Thorne ·
- Can VK2735 Be Taken Once a Month? What the Maintenance Study Actually Tested
Monthly VK2735 held up to 90% of weight already lost. Nobody started on monthly dosing, placebo held 61%, and the weight figures were exploratory endpoints.
By Allison Thorne ·
- Petrelintide Hit 9.2%. It Has Never Been Tested Against Semaglutide
Petrelintide reached 9.2% weight loss in type 2 diabetes. No trial has compared its side effects with semaglutide's, and Phase 3 will not either.
By Allison Thorne ·
- Trump Administration Plans Temporary Peptide Sales. Can Pharmacies Compound BPC-157 Now?
A newspaper reported a plan being drafted. Nothing has been announced and the restriction is unchanged. What the July vote did, and what BPC-157 was evaluated for.
By Allison Thorne ·
- Novo Has Agreed to Pay $300 Million for a Pill Nobody Has Taken
Novo has agreed to pay $300m up front, up to $2.6bn in total, for a GLP-1/GIP pill that has not entered phase 1. Its structure is undisclosed and the deal has not closed.
By Allison Thorne ·
- EloraTZP Hit 23.3%. It Is Not Beating Retatrutide Yet
Lilly's amylin and tirzepatide combination produced substantial weight loss in diabetes, but a cross-trial retatrutide comparison misses key differences and dropout rates.
By Allison Thorne ·
- The Retatrutide Trial Is Published. It Never Measured Muscle
TRIUMPH-1 appeared in the NEJM on 29 September: 28.3% at 80 weeks, dysesthesia at 12.5% against 0.9% on placebo, and no body composition data anywhere in it.
By Allison Thorne ·
- A Counterfeit Retatrutide Vial Put a Patient in the hospital. The Test Record Shows Where the Risk Sits
Australia's regulator traced a torn oesophagus to a vial that contained semaglutide, not retatrutide. Nearly 4,000 blind tests of online vials say the failures cluster in one channel.
By Allison Thorne ·
- What Is GLP-4? Bioglutide, NA-931 and What Tests Found
There is no GLP-4. The texts advertise an injectable vial of a compound its developer calls an oral capsule, and material sold under the name has tested as three different substances.
By Allison Thorne ·
- CagriSema Lost Its Head-to-Head. The Filing Is Unaffected
It missed non-inferiority in the only direct comparison. The filing is unaffected, because approval and beating the market leader are different questions.
By Allison Thorne ·
- When Will Retatrutide Be FDA Approved?
Lilly named the filing window in an SEC filing. Filing is not approval, the trials are done, and a prescription is realistically 2028 rather than next year.
- Compounded Semaglutide: What Actually Changed, and What Is Still Legal
The shortage route closed in 2025 and a narrower one remains. Two drugs, two dockets, four different deadlines, and a proposed rule that would close the rest.
- The FDA Warning Letters, and How Little It Took
Five letters posted at once. The striking part is how mild the cited claims were, and that bacteriostatic water and a dose calculator counted as evidence.
- Five More Peptides Go Before the FDA. What Is Actually Known About Them
GHK-Cu, Dihexa, LL-37, PEG-MGF and Melanotan II go before the FDA compounding panel by the end of February 2027. The evidence, the safety record, and why this slate is a harder case than July's.
- The July 2026 Peptide Vote: The Record, and What It Is Worth
An FDA advisory panel recommended six peptides for compounding against the written advice of the agency's own scientists. What the vote was, what it was not, and what a favorable vote on this list has historically been worth.